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Background:  Vitamin  D  regulates  the  renin–angiotensin  system,  suppresses  proliferation  of vascular
smooth  muscle  and  improves  endothelial  cell  dependent  vasodilatation.  These  mechanisms  may  play
a  role  on  pathogenesis  of  arterial  and  left  ventricular  stiffness.
Objectives:  We  aimed  to investigate  the  association  between  serum  25-hydroxyvitamin  D with  arterial
and  left  ventricular  stiffness  in  healthy  subjects.
Methods: We  studied  125 healthy  subjects  without  known  cardiovascular  risk  factors  or overt  heart  dis-
ease (mean  age:  60.2  ± 11.9  years).  Serum  25-hydroxyvitamin  D was  measured  using a direct  competitive
chemiluminescent  immunoassay.  The  subjects  were  divided  into  two  groups  according  to  the  serum  vita-
min D  level;  vitamin  D  sufﬁcient  (≥20  ng/ml,  n  = 56)  and vitamin  D  deﬁcient  (<20  ng/ml,  n =  69).  Indexes
of  LV  stiffness  such  as E/A and  E/E′ were  measured.  Pulse  wave  velocity  (PWV),  which  reﬂects  arterial
stiffness,  was  calculated  using  the  single-point  method  via  the  Mobil-O-Graph® ARC  solver  algorithm.
Results:  Systolic  blood  pressure,  level  of  serum  calcium,  PWV  and  E/E′ values  were  higher  and  E/A values
were lower  in  vitamin  D deﬁcient  group  compared  with  vitamin  D  sufﬁcient  group.  Multiple  linear  regres-
sion  analysis  showed  that  vitamin  D level  was independently  associated  with  E/E′ (  ˇ =  −0.364, p  <  0.001),
serum  calcium  (r =  −0.136,  p = 0.014),  PWV  (ˇ  = −0.203,  p  =  0.003),  E/A  (  ˇ = 0.209,  p =  0.001)  and  systolic
blood pressure  (ˇ  =  −0.293,  p < 0.001).
Conclusion:  25-Hydroxyvitamin  D  levels  are  associated  with  increased  ventricular  and arterial  stiffness
as well  as  systolic  blood  pressure  in  healthy  subjects.
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Serum 25-hydroxyvitamin D deﬁciency or insufﬁciency is
 substantially prevalent condition in the general population
1]. Vitamin D deﬁciency is associated with risk for cardio-
ascular event in the general population [2,3]. Also, vitamin
 deﬁciency is independently associated with cardiovascular
orbidity and mortality in the general population [4]. In con-
rast, vitamin D supplementation was signiﬁcantly associated
ith better survival, speciﬁcally in patients with documented
eﬁciency [5].
Arterial stiffness is an early marker of systemic atherosclerosis
nd a risk factor of hypertension [6,7]. There are several methods
o estimate arterial stiffness [8,9]. Among them, pulse wave veloc-
ty (PWV) is generally accepted as the most simple, non-invasive
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and validated indicator of arterial stiffness [9]. On the other hand,
ventricular stiffness is associated with left ventricular hypertrophy
(LVH) and delayed early diastolic ﬁlling which, in turn, increase
the risk of heart failure (HF), and death [10]. The left ventricu-
lar (LV) ﬁlling index (E/E′) and mitral peak early/peak late ﬂow
(E/A) velocities are accepted parameters for noninvasive LV stiff-
ness.
Association between low vitamin D and arterial stiffness in
healthy subjects was  investigated in only one study [11]. However,
relationship between vitamin D and ventricular stiffness was  not
investigated so far. Vitamin D regulates the renin–angiotensin sys-
tem, suppresses proliferation of vascular smooth muscle, increases
vascular calciﬁcation and improves endothelial cell dependent
vasodilatation [12–14]. Our hypothesis was  that vitamin D deﬁ-
ciency will be associated with both increased arterial and left
ventricular stiffness in healthy subjects. Therefore, in this cross sec-
tional study, we aimed to evaluate the association between serum
vitamin D with arterial and left ventricle stiffness in completely
healthy subjects.
vier Ltd. All rights reserved.
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tudy population
We  studied 125 (67 male, 58 female and mean age: 60.2 ± 11.9
ears) healthy subjects who had no known cardiovascular disease
r risk factors. The subjects were divided into two groups accord-
ng to the serum vitamin D level; vitamin D sufﬁcient (≥20 ng/ml,
 = 56) and vitamin D deﬁcient (<20 ng/ml, n = 69). All subjects, from
he nonmedical staff of our hospital or their relatives, had no car-
iac symptoms normal electrocardiogram. None of the individuals
articipating in the study were taking calcium or vitamin D supple-
ents. Patients with systemic disorder, cardiovascular disease or
isk factors, LV systolic dysfunction (LVEF < 50%), regional LV wall
otion abnormality, moderate or severe valvular heart disease,
trial ﬁbrillation or ﬂatter and receiving any drugs were excluded
rom the study. Institutional ethics committee approved the study
nd written informed consent for participation in the study was
btained from all individuals.
Blood pressure measurements used in the study were taken with
 mercury sphygmomanometer. Body mass index (BMI) was  com-
uted as weight divided by height squared (kg/m2). Body surface
rea of all subjects was computed (m2).
lood samples
Blood samples were drawn in the morning after a 20-min rest
ollowing a fasting period of 12 h. Glucose, creatinine and lipid
roﬁles for blood samples were analyzed for each patient. High-
ensitivity C reactive protein (hs-CRP) was measured using a BN2
odel nephlometer (Scil Diagnostics GmbH, Viernheim, Germany).
erum calcium (8.2–10.2 mg/dl) level was measured in all subjects.
erum 25-hydroxyvitamin D was measured using a direct compet-
tive chemiluminescent immunoassay (Elecsys; Roche Diagnostics,
annheim, Germany).
chocardiography
Doppler echocardiography studies had been performed by 2
ndependent investigators who were blinded to all information
bout individuals participating in the study.
Standard 2-dimensional and Doppler echocardiographies were
erformed using a commercially available echocardiographic
achine (Vivid 7R GE Medical System, Horten, Norway). LV end-
iastolic diameters (LVDd), end-diastolic interventricular septal
hickness (IVSth) and end-diastolic left ventricular posterior wall
hickness (PWth) were measured at end-diastole according to
stablished standards of the American Society of Echocardiogra-
hy [15]. LV ejection fraction (EF) was determined by the biplane
impson’s method [16].
Left ventricular mass (LVM) was calculated using
he Devereux formula [17]: LVM = 1:04[(LVDd + IVSth + PWth)3
 (LVDd)3] − 13.6. Thereafter, LV mass index (LVMI) was  obtained
y the following formula: LVM/body surface area.
onventional and tissue Doppler measurements
Mitral ﬂow velocities were recorded in the apical 4-chamber
iew. Mitral inﬂow measurements included peak early (E) and
eak late (A) ﬂow velocities and the E/A ratio. The tissue Doppler
f the mitral annulus movement was obtained from the apical 4-
hamber view. A 1.5-mm sample volume was placed sequentially
t the lateral and septal annular sites. The analysis was  performed
or early diastolic (E′), and late diastolic (A′) peak tissue velocities.
s a noninvasive parameter for LV stiffness, the LV ﬁlling index
E/E′), calculated by the ratio of transmitral ﬂow velocity to annularlogy 62 (2013) 361–365
velocity, was  determined. Adequate mitral and TDI signals were
recorded in all patients [18].
Measurement of the pulse wave velocity (PWV)
Pulse wave velocity was  calculated using the single-point
method (the so-called regression method) via the Mobil-O-Graph®
ARCsolver algorithm (IEM; Stolberg, Germany). PWV  calculation
includes person-related and dynamically measured result val-
ues. The measurement enables evaluation of arterial elasticity,
i.e. impedance. Aortal pressure, stroke volume, ﬂow and pressure
curves are taken into account, thus establishing a relation to indi-
vidual pulse wave velocity.
Statistical analysis
All analyses were conducted using SPSS 17.0 (SPSS for Win-
dows 17.0, Chicago, IL). Comparison of categorical variables
between the groups was performed using the Chi square (2)
test. Independent-samples T test was used in the analysis of con-
tinuous variables. Analysis of normality was performed with the
Kolmogorov–Smirnov test. The correlations between vitamin D and
laboratory, hemodynamic and echocardiographic parameters were
assessed by the Pearson correlation test. Multiple linear regression
analysis was performed to identify the independent associations of
vitamin D. p < 0.05 was considered statistically signiﬁcant.
Results
Comparison of baseline, laboratory and echocardiographic ﬁnd-
ings between the groups was showed in Table 1. Systolic blood
pressure, level of serum calcium, PWV  and E/E′ values were higher
and E/A values were lower in vitamin D deﬁcient group compared
with vitamin D sufﬁcient group (p < 0.05, for all).
Associations of vitamin D were demonstrated in Table 2.
Vitamin D was  signiﬁcantly associated with PWV  (r = −0.554,
p < 0.001), systolic blood pressure (r = −0.572, p < 0.001), serum
calcium (r = −0.213, p = 0.018), (E/A (r = 0.424, p < 0.001) and E/E′
(r = −0.602, p < 0.001). Relationships between vitamin D with PWV,
E/E′ and E/A were showed in Figs. 1–3.
Systolic blood pressure was  also signiﬁcantly correlated with
PWV (r = 0.253, p = 0.004), E/A (r = −0.381, p < 0.001) and E/E′
(r = 0.354, p < 0.001).
Multiple linear regression analysis showed in Table 2 that vita-
min  D level was  independently associated with E/E′ (  ˇ = −0.364,
p < 0.001), serum calcium (r = −0.136, p = 0.014), PWV  (  ˇ = −0.203,
p = 0.003), E/A (  ˇ = 0.209, p = 0.001) and systolic blood pressure
(  ˇ = −0.293, p < 0.001).
Discussion
The main ﬁndings of the present study were that; (1) patients
with vitamin D deﬁcient group have higher PWV, serum calcium,
E/E′ and systolic blood pressure values and lower E/A values com-
pared with patients with vitamin D sufﬁcient group; (2) Vitamin
D level was  independently associated with PWV, serum calcium,
E/E′, E/A and systolic blood pressure on multiple linear regression
analysis.
Increasing interest has focused on the role of vitamin D as it
relates to the cardiovascular system. Recent clinical studies have
associated low levels of 25-hydroxyvitamin D with hypertension,
coronary artery calciﬁcation, and cardiovascular diseases such as
myocardial infarction, acute stroke, congestive heart failure, and
diabetes mellitus [19–24].
T. S¸ eker et al. / Journal of Cardiology 62 (2013) 361–365 363
Table  1
Comparison of baseline, laboratory, and echocardiographic ﬁndings between groups.
Variables Vitamin D deﬁcient (n = 69) Vitamin D sufﬁcient (n = 62) p-Value
Baseline characteristics
Age (years) 58.7 ± 10.3 62.0 ± 13.4 0.131
Gender (male), n (%) 31 (49.2) 36 (58.1) 0.208
BMI  (kg/m2) 28.7 ± 4.5 28.1 ± 4.0 0.438
BSA  (m2) 1.79 ± 0.29 1.87 ± 0.33 0.143
SBP  (mmHg) 127.3 ± 6.6 117.1 ± 7.6 <0.001
DBP  (mmHg) 77.0 ± 5.3 77.9 ± 5.1 0.602
Heart  rate (beat/min) 76.1 ± 14.4 75.7 ± 9.3 0.835
Laboratory ﬁndings
Fasting glucose (mg/dl) 93.0 ± 12.7 92.7 ± 12.4 0.312
Total  cholesterol (mg/dl) 194.0 ± 42.8 199.4 ± 41.9 0.694
Triglyceride (mg/dl) 176.3 ± 108.5 177.4 ± 115.4 0.789
HDL-C (mg/dl) 44.8 ± 11.7 43.7 ± 10.2 0.926
LDL-C (mg/dl) 120.3 ± 35.1 130.0 ± 34.6 0.315
Creatinine (mg/dl) 0.75 ± 0.21 0.78 ± 0.15 0.213
Serum calcium (mg/dl) 10.4 ± 3.6 9.2 ± 2.5 0.01
Hs-CRP (mg/dl) 0.47 ± 0.46 0.51 ± 0.45 0.858
Uric  acid (mg/dl) 5.0 ± 1.7 5.2 ± 1.3 0.815
Echocardiographic ﬁndings
LVID (mm)  43.5 ± 4.5 45.2 ± 4.8 0.489
LAD  (mm) 34.0 ± 5.9 34.6 ± 5.4 0.636
LVMI  (g/m2) 96.2 ± 26.0 99.1 ± 24.9 0.876
Ejection fraction (%) 63.8 ± 3.8 63.6 ± 3.5 0.388
E  (cm/s) 71.0 ± 11.2 71.8 ± 10.6 0.459
A  (cm/s) 79.2 ± 19.8 62.5 ± 14.7 <0.001
E/A  0.94 ± 0.24 1.19 ± 0.22 <0.001
Em  6.6 ± 1.4 9.4 ± 1.5 <0.001
Am  9.0 ± 1.9 7.5 ± 1.6 <0.001
E/E′ 11.2 ± 2.8 7.8 ± 1.2 <0.001
Arterial stiffness parameter
PWV  (m/s) 9.2 ± 1.9 7.8 ± 1.6 <0.02
BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; LVID, left ventricular inner dimension; LAD, left atrium dimension; LVMI, left ventricular mass index;
PWV,  pulse wave velocity.
Table 2
Bivariate and multivariate relationships of 25-hydroxyvitamin D.
Variables Pearson correlation coefﬁcient p-Value Standardized  ˇ regression coefﬁcients p-Value
Serum calcium (mg/dl) −0.213 0.018 −0.136 0.014
SBP  (mmHg) −0.572 <0.001 −0.293 <0.001
PWV  (m/s) −0.554 <0.001 −0.203 0.003
E/A  0.545 <0.001 0.209 0.001
E/E′ −0.654 <0.001 −0.364 <0.001
SBP, systolic blood pressure; PWV, pulse wave velocity.
Fig. 1. Relationship between 25-hydroxyvitamin D and pulse wave velocity. Fig. 2. Relationship between 25-hydroxyvitamin D and E/E′ .
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ventricular and arterial stiffness as well as systolic blood pressure
in healthy subjects. Arterial stiffness plays a role on pathogenesis ofFig. 3. Relationship between 25-hydroxyvitamin D and E/A.
Present study showed that vitamin D was independently asso-
iated with both aortic stiffness and LV stiffness indexes such as
atios of E/A and E/E′ in healthy subjects. The present study is the
rst study in the literature, which evaluate the association between
itamin D and LV ventricular stiffness in healthy subjects. The asso-
iation between low vitamin D and increased arterial stiffness was
emonstrated in previous studies [11,25]. But this relationship was
nvestigated in only one study in healthy subjects [11]. In that study,
l Mheid et al. reported that vitamin D insufﬁciency was associ-
ted with increased arterial stiffness and endothelial dysfunction
n the conductance and resistance blood vessels in humans [11].
he precise pathophysiological mechanisms underlying vitamin D
eﬁciency-mediated ventricular and aortic stiffness still remain
nclear. However, several plausible mechanisms can explain how
itamin D may  inﬂuence both ventricular and arterial stiffness.
olecular and cell biology researches have shown vitamin D recep-
ors (VDR) to be present on vascular smooth muscle, endothelium,
nd cardiomyocytes [26] and possess the enzymatic system to con-
ert the primary circulating form of vitamin D, 25-hydroxyvitamin
 (25-OH D), to the active form, 1,25-dihydroxyvitamin D [12,27].
itamin D inﬂuences cardiomyocytes and vascular smooth mus-
le cell function by exerting antiproliferative effects [6]. Restriction
f LV ﬁlling is associated with ventricular diastolic stiffening due
o ventricular structural changes, such as interstitial ﬁbrosis or LV
ypertrophy [28,29]. It has been known that vitamin D receptors
n cardiomyocytes promote proliferation [14]. Animal models have
onsistently demonstrated that vitamin D can act as an antihyper-
rophic hormone in the heart [30–32]. In the Baltimore Longitudinal
tudy of Aging cohort, Ameri et al. [33] reported that vitamin D suf-
ciency (25(OH)D > 30 ng/mL) is associated with a reduced risk of
V concentric remodeling in healthy, community-dwelling individ-
als.
Moreover, vitamin D also affects the vascular and cardiac walls
y regulating the renin–angiotensin–aldosterone system (RAAS)
12–14,32]. Vitamin D deﬁciency predisposes to up-regulation
f the renin–angiotensin–aldosterone system and hypertrophy of
oth the left ventricle and vascular smooth muscle cells [34]. In
itamin D-deﬁcient animals there is an increased activation of the
ardiac RAAS system was observed in vitamin D-deﬁcient animals
nd has been linked to increased incidence of hypertension, left
entricular hypertrophy, and atherosclerosis [35].
Natriuretic peptides are secreted by cardiomyocytes due to vol-
me  overload and increased atrial and/or ventricular pressure.logy 62 (2013) 361–365
Previous studies reported that 1,25(OH)2D inhibits the secretion
of natriuretic peptides in atrial and ventricular myocytes [35–37].
Chen et al. concluded that the vitamin D-dependent suppression of
ANP reﬂects a global antagonism of myocardial hypertrophy rather
than an isolated inhibition of the ANP gene [38]. Interestingly, lig-
anded VDR was also shown to increase the expression and activity
of the type 1 natriuretic peptide receptor-A, which exerts antihy-
pertensive effects, suppresses the RAAS, and inhibits myocardial
hypertrophy and ﬁbrosis [38]. Activation of the RAAS and natri-
uretic peptides are some of the postulated mechanisms responsible
for vitamin D deﬁciency-mediated ventricular and aortic stiffness
[36].
Another possible mechanism which explains how vitamin D
may  inﬂuence both ventricular and arterial stiffness is calcium
homeostasis. Calcium ﬂux and calcium homeostasis are crucial
for the electrophysiology and contractility of the heart. Vita-
min  D increase vascular calciﬁcation, which contribute to the
increase in arterial stiffness [23]. 1,25-Hydroxyvitamin D was
shown to increase the Ca2+ uptake in cardiac ventricular cells.
1,25-Hydroxyvitamin D effects on cardiac contractility and intra-
cellular calcium handling were studied in an experimental study
[39]. In that study, the main result was  an accelerated relaxation in
response to acute and sustained administration of calcitriol [39]. In
our study, we showed that patients with vitamin D deﬁcient group
had higher serum calcium level than patients with vitamin D sufﬁ-
cient group and vitamin D level was  independently associated with
serum calcium. Our results supposed the possibility of relationship
between vitamin D level and aortic and ventricular stiffness.
Present study also showed that vitamin D was independently
associated with systolic blood pressure in healthy subjects. Our
ﬁndings related with blood pressure are compatible with the pre-
vious studies [40,41]. The majority of large cross-sectional studies
have demonstrated an inverse relationship between 25-OH D levels
and blood pressure, and the risk of future hypertension seems to be
greater in those with vitamin D deﬁciency [40,41]. Human studies
indicate that 1,25(OH)2D inhibits renin synthesis, which may  lower
blood pressure [11]. In the NHANES III study, the mean systolic
blood pressure was about 3 mm Hg lower in those in the individ-
uals in the highest quintile of serum 25-OH D levels compared with
those in the lowest quintile [42]. Furthermore, a previous study in
post-menopausal women reported a 7.8-mmHg reduction in sys-
tolic blood pressure with vitamin D replacement [43].
Study limitations
The present study has some signiﬁcant limitations: It has been
known that serum vitamin D levels vary with region, seasona-
lity and altitude due to possible effect of sunlight. The half-life
of vitamin D is approximately 3 weeks half-life, but serum vita-
min  D levels may  change throughout the day and season of
the year. So, a single measurement may  not reﬂect actual vita-
min  D status. 1,25-Dihydroxyvitamin D3 is the active metabolite.
1,25-Dihydroxyvitamin D3 was  not measured in present study.
However, 25-hydroxyvitamin D has important autocrine and
paracrine roles in the synthesis of 1,25-dihydroxyvitamin D3 and
determining intracellular levels of 1,25-dihydroxyvitamin D3 [44].
Conclusion
Low 25-hydroxyvitamin D levels are associated with increasedhypertension, while ventricular stiffness plays a role pathogenesis
of heart failure. Therefore, vitamin D may  be a role in pathogenesis
of both hypertension and heart failure.
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